Zidovudine

CHEMBL129 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
267.2 g/mol
LogP
Phase
4

This antiretroviral medication (also known as AZT) was the first approved treatment for HIV infection and works by blocking reverse transcriptase, an enzyme the virus needs to copy its genetic material. It is now used as part of combination antiretroviral therapy and is also given to HIV-positive pregnant women and their newborns to reduce the risk of transmitting HIV from mother to child. Bone marrow suppression causing anemia is the main side effect requiring monitoring.

Moleküler Ağırlık

267,2400 g/mol

LogP

0,00

TPSA

93,20 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O

InChI

InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1

Molecular Formula

C10H13N5O4

HBD / HBA

2 / 6

Döndürülebilir Bağlar

3

Ağır Atomlar

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This antiretroviral medication (also known as AZT) was the first approved treatment for HIV infection and works by blocking reverse transcriptase, an enzyme the virus needs to copy its genetic material. It is now used as part of combination antiretroviral therapy and is also given to HIV-positive pregnant women and their newborns to reduce the risk of transmitting HIV from mother to child. Bone marrow suppression causing anemia is the main side effect requiring monitoring.

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Yes, Zidovudine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL129. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 35370. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.